Sareum Holdings plc (SAR.L)
LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:28PM GMT
| Previous Close | 125.00 |
| Open | 0.00 |
| Bid | 120.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 135,482 |
| Market Cap | 89.341M |
| Beta (5Y Monthly) | -0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings Date | Feb 20, 2023 - Feb 24, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Following a 32% decline over last year, recent gains may please Sareum Holdings plc (LON:SAR) institutional owners
A look at the shareholders of Sareum Holdings plc ( LON:SAR ) can tell us which group is most powerful. With 55% stake...
- Simply Wall St.
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum Holdings PLC (“Sareum” or the “Company”) Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory AgencySareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in 2022, with
© 2023 Yahoo. All rights reserved.
